Slingshot members are tracking this event:
NTLA in vivo Hepatitis B Virus (HBV) program by Intellia, based on CRISPR/Cas9 genetic editing system, set for HBV animal trials in 2017
- Source Link:
Slingshot Insights Explained
May 01, 2018
Don’t see a project related to the catalyst you care about?
Related Keywords Hbv, Crispr-cas9, Gene-editing, Animal Trials